The 340B Program Soared to $38 Billion in 2020—Up 27% vs. 2019
Despite what you may have heard, the 340B Drug Pricing Program continues to thrive.
340B In The News
Biden Budget Offers Potential Oversight Tool on 340B Program
Citizens Against Government Waste (CAGW) has called for reforming the 340B program since 2014. The 340B safety net program was
Summit: 340B an out-of-control train
Originally intended as a way to help provide health care to uninsured and underinsured Americans, the 340B program has mutated
Congress should act on overwhelming support for changes to vital drug discount program
Over the last year, the pandemic has upended our normal lives, exacerbated health inequities, and tested the resiliency of our
“340B Drug Discount Program Should Be on GAO’s High-Risk List”
When a new Congress begins, the Government Accountability Office (GAO) releases its updated “High-Risk List” of programs and operations that
“Congress Must Ensure Patients, Not Corporations, Benefit from 340B Drug Program”
With the expansion of coverage of healthcare in 2010 through the Affordable Care Act, much changed in our efforts to
“It’s time to reevaluate 340B intermediary relationships and ask who they serve”
Citing compliance concerns, specifically duplicate discounts, several drug manufacturers took steps to reduce contract pharmacy access to 340B-priced drugs. The
“To Keep Drug Costs Down and Fairness Up, Stop the Abuses of 340B”
Alas, hospitals and pharmacies are abusing a federal program meant to help low-income patients. New research from consulting firm Berkeley
“340B Program Should Be Kept & Corrected”
With the election behind us, I’m glad that our elected leaders can stop focusing on getting elected and start focusing
“Discount drug plan needs congressional reform”
In the 340B program, drug manufacturers provide medications at steep discounts, with the intent of those discounts being passed along